Mizuho lowered the firm’s price target on LivaNova (LIVN) to $50 from $60 and keeps an Outperform rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- Enovis names Damien McDonald as CEO, succeeding Matt Trerotola
- LivaNova’s Reduced Liability and Strong Cash Position Justify Buy Rating
- LivaNova Faces €333 Million Liability Ruling
- Positive Outlook for LivaNova Driven by Product Upgrades and Market Expansion
- LivaNova price target lowered to $56 from $58 at Barclays